» Articles » PMID: 26342486

Gastric Hypersecretory States: Investigation and Management

Overview
Specialty Gastroenterology
Date 2015 Sep 7
PMID 26342486
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Hypersecretory conditions affecting the stomach account for significant morbidity and mortality manifested in some cases with peptic ulcer, gastrointestinal hemorrhage, and/or gastroesophageal reflux disease (GERD). The diagnosis of gastric acid hypersecretory states can be challenging and relies on the use of quantitative assays to measure gastric acid secretion and serum gastrin. The most common etiology for hypergastrinemia is the use of potent gastric acid inhibitors such as the proton pump inhibitors. The differential diagnosis of this condition is of critical importance, and will dictate management decisions. Conditions such as atrophic gastritis are relatively benign and can lead to hypergastrinemia without the presence of gastric acid hypersecretion. Zollinger-Ellison syndrome, on the other hand, causes hypergastrinemia with profound gastric acid hypersecretion [1]. More common causes of hypergastrinemia include gastric outlet obstruction, ileus, and chronic renal failure [2]. In most cases, proton pump inhibitors will be used to manage these conditions. In some instances, surgical therapy may be required. This chapter will review the important clinical causes of gastric acid hypersecretion and provide insights to the best medical management options to better care for patients with these disorders.

Citing Articles

Both pathogen and host dynamically adapt pH responses along the intestinal tract during enteric bacterial infection.

Woodward S, Neufeld L, Pena-Diaz J, Feng W, Serapio-Palacios A, Tarrant I PLoS Biol. 2024; 22(8):e3002761.

PMID: 39146372 PMC: 11349234. DOI: 10.1371/journal.pbio.3002761.


Long-Term Proton Pump Inhibitor-Acid Suppressive Treatment Can Cause Vitamin B Deficiency in Zollinger-Ellison Syndrome (ZES) Patients.

Ito T, Ramos-Alvarez I, Jensen R Int J Mol Sci. 2024; 25(13).

PMID: 39000391 PMC: 11242121. DOI: 10.3390/ijms25137286.


Prediction of gastroesophageal reflux episodes by smooth muscle electromyography: A translational study in rats and adolescents.

Nagy A, Szucs K, Grosz G, Sule M, Fekete F, Karoliny A Heliyon. 2023; 9(8):e18859.

PMID: 37609397 PMC: 10440461. DOI: 10.1016/j.heliyon.2023.e18859.


Phenytoin Toxicity with High Dose, Concomitant Ascorbic Acid Dosing.

Schuh M, Mustain K, Crosby S Innov Pharm. 2023; 13(4).

PMID: 37305595 PMC: 10256283. DOI: 10.24926/iip.v13i4.5122.


Gastric Cancer Risk Was Associated with Dietary Factors Irritating the Stomach Wall: A Case-Control Study in Korea.

Kim S, Kwak J, Eun C, Han D, Kim Y, Song K Nutrients. 2022; 14(11).

PMID: 35684033 PMC: 9183208. DOI: 10.3390/nu14112233.


References
1.
Metz D, Sostek M, Ruszniewski P, Forsmark C, Monyak J, Pisegna J . Effects of esomeprazole on acid output in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion. Am J Gastroenterol. 2007; 102(12):2648-54. DOI: 10.1111/j.1572-0241.2007.01509.x. View

2.
Fallone C, Mayrand S . Gastroesophageal reflux and hyperacidity in chronic renal failure. Perit Dial Int. 2002; 21 Suppl 3:S295-9. View

3.
Weinstein D, deRijke S, Chow C, Foruraghi L, Zhao X, Wright E . A new method for determining gastric acid output using a wireless pH-sensing capsule. Aliment Pharmacol Ther. 2013; 37(12):1198-209. PMC: 3703786. DOI: 10.1111/apt.12325. View

4.
Ghosh T, Lewis D, Axon A, Everett S . Review article: methods of measuring gastric acid secretion. Aliment Pharmacol Ther. 2011; 33(7):768-81. DOI: 10.1111/j.1365-2036.2010.04573.x. View

5.
Metz D, Soffer E, Forsmark C, Cryer B, Chey W, Bochenek W . Maintenance oral pantoprazole therapy is effective for patients with Zollinger-Ellison syndrome and idiopathic hypersecretion. Am J Gastroenterol. 2003; 98(2):301-7. DOI: 10.1111/j.1572-0241.2003.07262.x. View